Stocks · Healthcare · Biotechnology
Mirum Pharmaceuticals, Inc. MIRM
$82.93 -1.18% Close, Oct 2, 2026 · NASDAQ · Market cap $5.06B
Low risk
Next earnings report: Nov 3, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- The diluted share count rose 27.4% in a year.
- Revenue over the last four quarters was $618.1M, up 44.0% from a year earlier, slowing from 50.2% a quarter earlier.
- The stock is in a downtrend: below its 200-day average, with the 50-day average below the 200-day.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 18%
- Revenue growth, 3-year CAGRTop 8%
- Revenue growth accelerationBottom 23%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 45%
- Gross marginTop 29%
- Operating marginBottom 44%
- Accruals (lower is better)Top 5%
- Interest coverBottom 35%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 36%
- Free-cash-flow yieldBottom 38%
- EBITDA / enterprise valueBottom 33%
- Sales / enterprise valueBottom 34%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 41%
- 6-month returnBottom 30%
- 1-year return vs S&P 500Top 49%
- Distance from 52-week highBottom 45%
- Trend checklist (0–4)Bottom 14%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 5%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyTop 10%
- Upside to consensus price targetTop 44%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 27%
- Maximum drawdown, 3 yearsTop 9%
- Beta vs S&P 500 (lower is better)Top 29%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 50.2% | 44.0% | ↓ |
| Gross margin | 79.0% | 81.7% | ↑ |
| Operating margin | -13.3% | -17.4% | ↓ |
| FCF margin | -0.3% | -74.1% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 44.0% | 50.2% | ↓ | Top 18% |
| Gross margin | 81.7% | 79.0% | ↑ | Top 29% |
| Operating margin | -17.4% | -13.3% | ↓ | Bottom 44% |
| Net margin | -139.2% | -13.6% | ↓ | — |
| Free-cash-flow margin | -74.1% | -0.3% | ↓ | — |
| Return on invested capital | -13.1% | — | Top 45% | |
| Revenue growth, 3-year CAGR | 89.1% | — | Top 8% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -38.7%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 22.7%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -8.0 pp
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -8.0×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -11.44%
- Shareholder yield
- -11.44%
- Share count change, 1 year
- +27.4%
- Share count change, 3-year CAGR
- +18.5%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 5, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 4 of 8
- Average EPS surprise, last 4
- -100.0%
- Average 2-day reaction, last 8
- +1.6%
- Positive 20 days after report
- 3 of 8
Analysts
- Consensus price target
- $147.10
- Target vs current price
- +77.4%
- Analysts with a rating
- 18
- Share rating Buy or Strong Buy
- 100%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 5, 2026 | -42.8% | +1.4% | -5.8% | -5.7% | — |
| May 6, 2026 | -3257.5% | +4.0% | +1.0% | -13.2% | +0.1% |
| Feb 25, 2026 | -650.0% | +1.1% | -18.3% | -18.2% | -9.8% |
| Nov 4, 2025 | +150.0% | +0.2% | -1.6% | -1.4% | +45.7% |
| Aug 6, 2025 | +61.3% | +3.0% | +24.8% | +43.9% | +35.9% |
| May 7, 2025 | +23.1% | +0.5% | +10.4% | +8.8% | +26.9% |
| Feb 26, 2025 | -81.5% | +1.2% | -9.4% | -5.7% | -11.3% |
| Nov 12, 2024 | +33.3% | +1.6% | -0.5% | +6.0% | +21.3% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | -$1.06 | -$0.74 | -42.8% | $176.2M |
| May 6, 2026 | -$13.43 | -$0.40 | -3257.5% | $159.9M |
| Feb 25, 2026 | -$0.11 | $0.02 | -650.0% | $148.9M |
| Nov 4, 2025 | $0.05 | -$0.10 | +150.0% | $133.0M |
| Aug 6, 2025 | -$0.12 | -$0.31 | +61.3% | $127.8M |
| May 7, 2025 | -$0.30 | -$0.39 | +23.1% | $111.6M |
| Feb 26, 2025 | -$0.49 | -$0.27 | -81.5% | $99.4M |
| Nov 12, 2024 | -$0.30 | -$0.45 | +33.3% | $90.4M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 8.88× | — | — | Bottom 34% |
| Free-cash-flow yield | -9.06% | — | — | Bottom 38% |
| Earnings yield | -17.56% | — | — | Bottom 36% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✗ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -10.2%
- 200-day average slope (20 days)
- +2.4%
- Distance from 50-day average
- -15.5%
- Distance from 200-day average
- -15.6%
- RSI (14)
- 25.8
- Relative volume
- 1.49×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 43.9%
- Volatility vs own 5-year history
- 39th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.74
- Correlation with S&P 500
- 0.27
- Current drawdown from 1-year high
- -35.5%
- Maximum drawdown, 3 years
- -35.5%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Dec 11, 2020 | Nov 29, 2021 | -48.7% | 242 days | 89 days (Apr 6, 2022) |
| Aug 5, 2022 | Dec 27, 2022 | -40.3% | 99 days | 115 days (Jun 13, 2023) |
| Jul 8, 2026 | Oct 2, 2026 | -35.5% | 61 days | Not yet recovered |
| Apr 14, 2022 | Jun 28, 2022 | -33.0% | 50 days | 27 days (Aug 5, 2022) |
| Dec 15, 2023 | Apr 18, 2024 | -32.5% | 84 days | 54 days (Jul 8, 2024) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $5.06B
- EPS, diluted (TTM)
- -$14.56
- Revenue (TTM)
- $618.1M
- 52-week range
- $63.23 – $130.00
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $19.1M | $77.1M | $186.4M | $336.9M | $521.3M |
| Gross profit | $17.2M | $64.7M | $139.3M | $255.2M | $420.7M |
| Operating income | -$173.4M | -$131.2M | -$109.2M | -$87.6M | -$22.1M |
| Net income | -$84.0M | -$135.7M | -$163.4M | -$87.9M | -$23.4M |
| EPS (diluted) | -$2.77 | -$4.02 | -$4.00 | -$1.85 | -$0.47 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $90.4M | $99.4M | $111.6M | $127.8M | $133.0M | $148.9M | $159.9M | $176.2M |
| Net income | -$14.2M | -$23.8M | -$14.7M | -$5.9M | $2.9M | -$5.7M | -$790.2M | -$67.2M |
| EPS (diluted) | -$0.30 | -$0.49 | -$0.30 | -$0.12 | $0.05 | -$0.12 | -$13.43 | -$1.06 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$132.8M | -$120.1M | -$70.9M | $10.3M | $55.8M |
| Capital expenditure | -$19.0M | -$278,000 | -$20.1M | -$993,000 | -$954,000 |
| Free cash flow | -$151.8M | -$120.4M | -$91.1M | $9.3M | $54.9M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $6.9M | $107.4M | $216.7M | $17.7M | $40.1M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $438.3M
- Total assets
- $1.04B
- Total liabilities
- $1.06B
- Total debt
- $760.5M
- Net debt
- $429.8M
- Shareholders’ equity
- -$10.4M
As of Jun 30, 2026 (filed Aug 5, 2026).
Short interest
- Shares sold short
- 6,281,413
- Days to cover
- 11.99
- Change vs previous report
- +1.8%
FINRA short interest, settlement date Sep 15, 2026.